Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 12/20 | 0.58 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938437 | 0.87 | SMN1; SMN2 (0.47) | SCN5ASCN1ASCN2AALDH1A1AHR | |
| SCHEMBL23116008 | 0.83 | SCN5A (0.48) | SCN5ASCN1ASCN2AMETKDM4E | |
| SCHEMBL1159892 | 0.82 | SCN5A (0.41) | SCN5ASCN1ASCN2AAHRMET | |
| SCHEMBL4212574 | 0.81 | SCN5A (0.46) | SCN5ASCN1ASCN2AMETMEN1 | |
| SCHEMBL938219 | 0.78 | SCN5A (0.44) | SCN5ASCN1ASCN2ACYP1A2MET | |
| SCHEMBL23116011 | 0.78 | SCN5A (0.41) | SCN5ASCN1ASCN2AALDH1A1CYP1A2 | |
| SCHEMBL23116199 | 0.78 | SCN5A (0.41) | SCN5ASCN1ASCN2AMETKDM4E | |
| SCHEMBL31275134 | 0.78 | SCN5A (0.58) | SCN5ASCN1ASCN2AALDH1A1CYP1A2 | |
| SCHEMBL13757316 | 0.78 | SCN5A (0.59) | SCN5ASCN1ASCN2AALDH1A1CYP1A2 | |
| SCHEMBL5252065 | 0.78 | SCN5A (0.58) | SCN5ASCN1ASCN2AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129066-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2024229221-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | CAPULUS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| US-12030881-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030881-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030881-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220204505-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11279700-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11279700-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200377499-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20120046271-A1 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2012024397-A2 | 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| WO-2011014462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030881-B2 | Ion channel modulators | SCN1A, SCN1B, SCN2A | SCN5A 5/4885SCN1A 1/4885SCN2A 3/4885 |
| US-20120046271-A1 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin | HTR2B, HTR1B, HTR5A | SCN5A 159/4885SCN1A 377/4885SCN2A 371/4885 |
| US-11279700-B2 | Ion channel modulators | SCN1A, SCN1B, SCN2A | SCN5A 5/4885SCN1A 1/4885SCN2A 3/4885 |
| US-20220204505-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | SCN5A 5/4885SCN1A 1/4885SCN2A 3/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | SCN5A 354/4885SCN1A 681/4885SCN2A 1485/4885 |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | SCN5A 52/4885SCN1A 55/4885SCN2A 72/4885 |
| US-20250129066-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | SCN5A 5/4885SCN1A 1/4885SCN2A 3/4885 |
| US-20200377499-A1 | ION CHANNEL MODULATORS | SCN1A, SCN1B, SCN2A | SCN5A 5/4885SCN1A 1/4885SCN2A 3/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | SCN5A 1404/4885SCN1A 1826/4885SCN2A 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.